PALATIN TECHNOLOGIES, INC.

(PTN)
  Report
Delayed Nyse  -  05/13 04:00:00 pm EDT
0.3700 USD   +13.50%
04/22Palatin to present at eyecelerator @ american society of cataract and refractive surgery (ascrs) 2022
AQ
03/07TRANSCRIPT : Palatin Technologies, Inc. - Special Call
CI
03/04Palatin hosting key opinion leader webinar on dry eye disease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Palatin Technologies, Inc. Announces Initiation of Pivotal Phase 3 Pl9643 Melody-1 Clinical Trial in Patients with Dry Eye Disease

12/28/2021 | 07:30am EDT

Palatin Technologies, Inc. announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. The pivotal Phase 3 MELODY-1 clinical study is a multi-center, randomized, double–masked and vehicle–controlled study evaluating the safety and efficacy of the melanocortin agonist, PL9643 ophthalmic solution, compared to vehicle in subjects with dry eye disease (DED). The study design is based on positive Phase 2 results of PL9643 for the treatment of dry eye disease, and an end-of-phase 2 (EOP2) meeting with the with the U.S. Food and Drug Administration (FDA), reaching agreement on all key elements of a pivotal Phase 3 clinical program, including study design, endpoints, interim assessment, and patient population. In addition, to support a New Drug Application (NDA) filing, a second phase 3 study (MELODY-2) and long-term safety study (MELODY-3) will be required. If the program progresses as planned, top-line results from MELODY-1 would be available second half calendar 2022, MELODY-2 data read out second half calendar 2023, with a potential NDA submission first half calendar 2024.


ę S&P Capital IQ 2021
All news about PALATIN TECHNOLOGIES, INC.
04/22Palatin to present at eyecelerator @ american society of cataract and refractive surger..
AQ
03/07TRANSCRIPT : Palatin Technologies, Inc. - Special Call
CI
03/04Palatin hosting key opinion leader webinar on dry eye disease
AQ
02/16Palatin reports second quarter fiscal year 2022 financial results and provides corporat..
AQ
02/15TRANSCRIPT : Palatin Technologies, Inc., Q2 2022 Earnings Call, Feb 15, 2022
CI
02/15PALATIN TECHNOLOGIES : Reports Second Quarter Fiscal Year 2022 Financial Results and Provi..
PU
02/15PALATIN TECHNOLOGIES INC : Results of Operations and Financial Condition (form 8-K)
AQ
02/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
02/14PALATIN TECHNOLOGIES INC Management's Discussion and Analysis of Financial Condition a..
AQ
02/14Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Mont..
CI
More news
Analyst Recommendations on PALATIN TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2022 2,10 M - -
Net income 2022 -32,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,71x
Yield 2022 -
Capitalization 85,7 M 85,7 M -
Capi. / Sales 2022 40,9x
Capi. / Sales 2023 12,8x
Nbr of Employees 26
Free-Float 95,6%
Chart PALATIN TECHNOLOGIES, INC.
Duration : Period :
Palatin Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALATIN TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,37 $
Average target price 3,33 $
Spread / Average Target 801%
EPS Revisions
Managers and Directors
Carl Spana Director
Stephen T. Wills COO, CFO, Secretary, Treasurer & Executive VP
John K. A. Prendergast Director
Michael B. Raizman Chief Medical Officer
John Dodd Senior Vice President-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
PALATIN TECHNOLOGIES, INC.-27.68%86
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601